108903-26-0

Basic information

• Product Name: C₁₃H₁₇N₃O₃S
• Synonyms: C₁₃H₁₇N₃O₃S
• CAS NO: 108903-26-0
• Molecular Weight: 295.362
• Mol File: 108903-26-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: C₁₃H₁₇N₃O₃S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₁₇N₃O₃S(108903-26-0)
• EPA Substance Registry System: C₁₃H₁₇N₃O₃S(108903-26-0)

Safety Data

• Hazardous Substances Data: 108903-26-0(Hazardous Substances Data)

Upstream product

• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 41764-74-3 3,4-dimethoxybenzohydrazide 
• 57-06-7 N-allyl isothiocyanate 

Downstream Products

• 690247-30-4 2-[4-allyl-5-(3,4-dimethoxyphenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenylethanone 
• 122772-21-8 4-Allyl-5-(3,4-dimethoxy-phenyl)-4H-[1,2,4]triazole-3-thiol 

Relevant articles and documents

Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity

New N-4-piperazinyl ciprofloxacin-triazole hybrids 6a-o were prepared and characterized. The in vitro antimycobacterial activity revealed that compound 6a experienced promising antimycobacterial activity against Mycobactrium smegmatis compared with the reference isoniazide (INH). Additionally, compound 6a exhibited broad spectrum antibacterial activity against all the tested strains either Gram-positive or Gram-negative bacteria compared with the reference ciprofloxacin. Also, compounds 6g and 6i displayed considerable antifungal activity compared with the reference ketoconazole. DNA cleavage assay of the highly active compounds 6c and 6h showed a good correlation between the Mycobactrium cleaved DNA gyrase assay and their in vitro antimycobactrial activity. Moreover, molecular modeling studies were done for the designed ciprofloxacin derivatives to predict their binding modes towards Topoisomerase II enzyme (PDB: 5bs8).

1,2,4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities

A series of novel nitric oxide (NO) donating triazole/oxime hybrids was prepared and evaluated for their anti-inflammatory activity and antiproliferative activity. Most of the tested compounds showed significant anti-inflammatory activity using carrageenan-induced rat paw edema method compared to indomethacin. Calculation of the ulcer indices and histopathological investigation indicated that the prepared NO-donating oximes exhibited less ulcerogenicity compared to their ketone intermediates and indomethacin. The NO-donating oximes 7i and 7k achieved remarkable cell growth inhibition activity against most of the tested cell lines. Compound 7k was found to be with high selectivity against CNS subpanel with selectivity ratio of 11.99 at GI 50 level.

Synthesis of 5-aryl-3-mercapto-4-substituted-triazoles

-